Immune reconstitution after highly active antiretroviral treatment of HIV infection

  • Brigitte Autran
  • Guislaine Carcelain
  • Patrice Debre
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 495)


The introduction of highly active antiretroviral therapy (HAART) combining inhibitors of the HIV-1 reverse transcriptase and protease have dramatically modified the course of the HIV infection during the past four years. Despite some controversies about the extent to which the immune system can normalize, it is generally admitted nowadays that some immune reconstitution can be obtained in both asymptomatic HIV-infected individuals and AIDS patients and can confer host protection against opportunistic events (1-5). The best hallmark of such immune restoration is the massive decline in the mortality and morbidity related to AIDS that have been registered in all industrialized countries (6 7). Although these recent advances warrant optimism, the current HAART regimens are unable to eradicate the virus and to restore an HIV-specific immunity (8 9), except when introduced immediately after virus contamination (10). Nevertheless the immune reconstitution obtained with these antiretroviral drugs alone, even incomplete, has brought definitive evidences for the central role played by HIV itself in the massive immune alterations induced by such infection.


Immune Reconstitution Cell Repertoire Immune Restoration Cell Reconstitution Viral Load Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Autran, B., G. Carcelain, T.S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, and P. Debre, J. Leibowitch. 1997. Positive effects of combined anti-retroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.Science.277:112–116.PubMedCrossRefGoogle Scholar
  2. 2.
    Gorochov, G., A.U. Neumann, A. Kereveur, C. Parizot, T.S. Li, C. Katlama, M. Karmochkine, G. Raguin, B. Autran, and P. Debre. 1998. Perturbation of CD4 and CD8 T cell repertoires during progression to AIDS and influence of antiviral therapy.Nature Medicine.4(2):215–221.PubMedCrossRefGoogle Scholar
  3. 3.
    Li, T.S., R. Tubiana, C. Katlama, V. Calvez, H.A. Mohand, and B. Autran. 1998. Long lasting recovery in CD4+ T cell function mirrors viral load reduction after highly active anti-retroviral therapy in patients with advanced HIV disease.Lancet.351:1682–1686.PubMedCrossRefGoogle Scholar
  4. 4.
    Lederman, M.M., E. Connick, A. Landay, D.R. Kuritzkes, J. Spritzler, M. St Clair, B.L. Kotzin, L. Fox, M.H. Chiozzi, J.M. Leonard, F. Rousseau, M. Wade, J.D. Roe, A. Martinez, and H. Kessler. 1998. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of Zidovudine, Lamivudine and Ritonavir: results of AIDS clinical trials group protocol 315.J lnfect Dis.178:70–79.CrossRefGoogle Scholar
  5. 5.
    Pakker, N.G., D.W. Notermans, R.J. De Boer, M.T.L. Roos, F. De Wolf, A. Hill, J.M. Leonard, S.A. Danner, F. Miedema, and P.T.A. Schellekens. 1998. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation.Nat Med.(4)2:208–214.CrossRefGoogle Scholar
  6. 6.
    Hogg, R.S., M.W. O’Shaughnessy, N. Gataric, B. Yip, K. Craib, M.T. Schechter, and J.S. Montaner. 1997. Decline in deaths from AIDS due to new antiretrovirals.Lancet.349:1294.PubMedCrossRefGoogle Scholar
  7. 7.
    Palella, F.J., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, G.A. Satten, D.J. Aschman, S.D. Holmberg, and the HIV outpatient study investigators. 1998. Declining Morbidity and mortality among patients with advanced human immunodeficiency virus infection.N Engl J Med338(13):853–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Plana, M., F. Garcia, T. Gallart, J.M. Miro, and J.M. Gatell. 1998. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease.Lancet.352:1194–1195.PubMedCrossRefGoogle Scholar
  9. 9.
    Carcelain, G., R. Tubiana, T.S. Li, V. Calvez, N. Jouy, M. Jouan, M.A. Valantin, C. Olivier, P.M. Girard, P. Debré, C. Katlama, and B. Autran. 1999. Long-Term recovery in CD4+ T cell function with highly efficient antiretroviral therapy.6 th Conference on Retrovirus and Oppotunistic Infections .Chicago, USA.Google Scholar
  10. 10.
    Rosenberg, E.S, J.M. Billingsley, A.M. Caliendo, S.L. Boswell, P.E. Sax, S.A. Kalams, and B.D. Walker. 1997. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremie.Science.278:1447.PubMedCrossRefGoogle Scholar
  11. 11.
    Collier, A.C., R.W. Coombs, D.A. Schoenfeld, R.L. Bassett, J. Timpone, A. Baruch, J.M. Facey, C. Whitacre, V.J. McAuliffe, H.M. Friedman, T.C. Merigan, R.C. Reichman, C. Hooper, and L. Corey. 1996. Treatment of human immunodeficiency virus infection with saquinavir zidovudine and zalcitabine.N Engl JMed.334:1011–1017.CrossRefGoogle Scholar
  12. 12.
    Katzenstein, D.A., S.M. Hammer, M.D. Hugues, et al. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter.N Engl J Med.335:1091–1098.PubMedCrossRefGoogle Scholar
  13. 13.
    Hammer, S.M., K.E. Squires, M.D. Hughes, J.M. Grimes, L.M. Demeter, J.S. Currier, J.J. Eron, J.E. Feinberg, H.H. Balfour, L.R. Deyton, J.A. Chodakewitz, M.A. Fischl, and the ACTG 320 study team. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less.N Engl J Med.337(11):725–739.PubMedCrossRefGoogle Scholar
  14. 14.
    Renaud, M., C. Katlama, A. Mallet, V. Calvez, G. Carcelain, R. Tubiana, M. Jouan, E. Caumes, H. Agut, F. Bricaire, P. Debre, and B. Autran. 1999. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor containing antiretroviral regiment.AIDS.13:669–676.PubMedCrossRefGoogle Scholar
  15. 15.
    Hellerstein, M., M.B. Hanley, D. Cesar, S. Siler, C. Papageorgopoulos, E. Wieder, D. Schmidt, R. Hoh, R. Neese, D. Macallan, S. Deeks, and J.M. McCune. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans.Nat Med.5:83–89.PubMedCrossRefGoogle Scholar
  16. 16.
    Fleury, S., G.P. Rizzardi, A. Chapuis, G. Tambussi, C. Knabenhans, E. Simeoni, J. MeuwlyJ.Corpataux, A. Lazzarin, F. Miedema, and G. Pantaleo. 2000. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.Proc Natl Acad Sci USA.97:5393–5398.PubMedCrossRefGoogle Scholar
  17. 17.
    Mackall, C.L., L. Granger, M.A. Sheard, R. Cepeda, and R.E. Gress. 1993. T-cell regeneration after bone marrow transplantation: differential CD45 isoform expression on thymic-derived versus thymic-independent progeny.Blood.82:2585–2894.PubMedGoogle Scholar
  18. 18.
    Douek, D.C., R.D. McFarlard, P.H. Keiser, E.A. Gage, J.M. Massey, B.F. Haynes, M.A. Polis, A.T. Haase, M.B. Feinberg, J.L. Sullivan, B.D. Jamieson, J.A. Zack, L.J. Picker, and R.A. Koup. 1998. Changes in thymic function with age and during the treatment of HIV infection.Nature.396:690–695.PubMedCrossRefGoogle Scholar
  19. 19.
    Gorochov G., Neumann A., Parizot C., Li T.S., Katlama C., Debre P. Down regulation of CD8+ T cell expansions in HIV patients receiving highly active combinaison therapy..Blood.Sous presse 2001.Google Scholar
  20. 20.
    Hadley A.D., D.J. Dockrell, A. Algeciras; S. Ziesmer, A. Landay, M.M. Lederman, E. Connick, D. Kuritzkes, D.J. Lynch, P. Roche, H. Yagita, and C.V. Paya. 1998. In vivo analysis of Fas/Fas-L interactions in HIV-infected patients.J Clin. Invest.102:79–87.CrossRefGoogle Scholar
  21. 21.
    Bucy, R.P., R.D. Hockett, C.A. Derdeyn, M.S. Saag, K. Squires, M. Sillers, R.T. Mitsuyasu, and J.M. Kilby. 1999. Initial increase in blood CD4+ lymphocytes after HIV retroviral therapy reflects redistribution form lymphoid tissus.J. Clin. Invest.103:13911398.Google Scholar
  22. 22.
    Rinaldo, C.R., J.M. Liebman, X.L. Huang, Z. Fan, A.L. Shboul, D.K. McMahon DKet al.1999. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.J Infect Dis.179:329–336.PubMedCrossRefGoogle Scholar
  23. 23.
    Pontselli, O., S. Kerkhof-Garde, D.W. Notermans, N.A. Foudraine, M.T. Roos, M.R. Kleinet al.1999. Functional T cell reconstitution and human immunodeficiency virus-lspecific cell-mediated immunity during highly active antiretroviral therapy.J Infect Dis.180:76–86.CrossRefGoogle Scholar
  24. 24.
    De Jong, M.D., R.J. De Boeer, and F. De Wolf. 1997. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.AIDS.11:F79–F84.PubMedCrossRefGoogle Scholar
  25. 25.
    Neumann, A.U., R. Tubiana, V. Calvez, C. Robert, T.S. Li, H. Agut, B. Autran, C. Katlama and the Comet study group. 1999. HIV-1 rebound during interruption of HAART has no deleterious effect on reinitiated treatment.AIDS.13:677–683.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Brigitte Autran
    • 1
  • Guislaine Carcelain
    • 1
  • Patrice Debre
    • 1
  1. 1.Laboratoire d’Immunologie Cellulaire et Tissulaire, INSERM U543Hôpital Pitié-Salpétrière, Bâtiment CERVIParisFrance

Personalised recommendations